149 Results for "

EGFR/HER2

" in MedChemExpress (MCE) Product Catalog:
Products (149)

149 Results for "EGFR/HER2" in MCE Product Catalog:

113
113 Publications Verification
Cat. No.: HY-10261
CAS No.: 850140-72-6
Purity:  99.92%
Synonyms: BIBW 2992
Research Areas:  

Cancer

Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
loading...
    loading...
113
113 Publications Verification
Cat. No.: HY-10261A
CAS No.: 850140-73-7
Purity:  99.74%
Synonyms: BIBW 2992MA2
Research Areas:  

Cancer

Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-32721
CAS No.: 698387-09-6
Synonyms: HKI-272
Target:  

EGFR

Research Areas:  

Cancer

Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-32721B
CAS No.: 915942-22-2
Synonyms: HKI-272 maleate
Target:  

EGFR

Research Areas:  

Cancer

Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-104065
CAS No.: 1269662-73-8
Purity:  99.89%
Synonyms: SHR-1258
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-104065B
CAS No.: 1397922-61-0
Purity:  98.01%
Synonyms: SHR-1258 dimaleate
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-135815
CAS No.: 1847461-43-1
Purity:  99.60%
Synonyms: TAK-788; AP32788
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-135815A
CAS No.: 2389149-74-8
Purity:  99.83%
Synonyms: TAK-788 succinate; AP32788 succinate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-13501
CAS No.: 366017-09-6
Purity:  99.76%
Synonyms: TAK-165
Target:  

EGFR

Research Areas:  

Cancer

Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15730
CAS No.: 1092364-38-9
Purity:  99.96%
Synonyms: HM781-36B; NOV120101
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

Poziotinib (HM781-36B) is an orally active, irreversible pan-HER inhibitor, which effectively inhibits EGFR wt, HER-2 and HER-4 with IC50s of 3.2, 5.3 and 23.5 nM, respectively. Poziotinib (HM781-36B) also shows excellent inhibitory activities against mutated EGFRs, including EGFR T790M and EGFR L858R/T790M, with IC50s of 4.2 and 2.2 nM, respectively. Excellent antitumor activity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-10223
CAS No.: 1012054-59-9
Purity:  99.05%
Target:  

EGFR HDAC

Research Areas:  

Cancer

CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P0221
CAS No.: 137061-48-4
Synonyms: Pituitary Adenylate Cyclase Activating Polypeptide 38
PACAP (1-38), human, ovine, rat is a PAC1 receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC50s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca 2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-132842
CAS No.: 2370013-12-8
Purity:  99.71%
Synonyms: DZD9008
Target:  

EGFR Btk

Research Areas:  

Cancer

Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13314
CAS No.: 781613-23-8
Purity:  99.41%
Synonyms: XL-647; EXEL-7647; KD-019
Target:  

EGFR VEGFR Src

Research Areas:  

Cancer

Tesevatinib (XL-647) is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib can inhibit tumor proliferation and exhibits antitumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N1073
CAS No.: 51225-30-0
Synonyms: 6-Isopentenylgenistein; Erythrinin B
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR L858R/T790M mutation, and fungal infections .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15196
CAS No.: 871026-44-7
Purity:  99.70%
Target:  

EGFR

Research Areas:  

Cancer

TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148810
CAS No.: 2728667-27-2
Purity:  99.74%
Synonyms: BI 1810631
Target:  

c-Met/HGFR

Research Areas:  

Cancer

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10261B
CAS No.: 439081-18-2
Purity:  99.98%
Synonyms: (E/Z)-BIBW 2992
Research Areas:  

Others Cancer

(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10530
CAS No.: 845272-21-1
Purity:  98.07%
Synonyms: ASLAN001; ARRY-334543
Target:  

EGFR

Research Areas:  

Cancer

Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99275
CAS No.: 1262787-83-6
Synonyms: AMG-888; U3-1287

Target:  

EGFR Akt ERK PARP Survivin

Research Areas:  

Cancer

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
loading...
    loading...